CHIP – Medxy AI

TP53-Mutated Clonal Hematopoiesis Drives Pro-Inflammatory Phenotype and Predicts Poor Outcomes After CAR T-Cell Therapy

By MedXY 08/26/2026

TP53-mutant clonal hematopoiesis in CAR T-cell recipients is linked to a pro-inflammatory state, cytopenias, and worse survival, highlighting the importance of tailored monitoring strategies in this high-risk group.

Hematology-Oncology news Oncology

Pre-diagnostic Clonal Hematopoiesis Raises Risk of Second Cancers in Patients With Primary Cancer

By MedXY 06/08/2026

Patients with primary cancer who had pre-diagnostic CHIP faced a higher risk of second cancers, especially blood cancers. The findings suggest CHIP may help identify survivors who need closer long-term monitoring.

news Pediatrics Public Health Specialties

Navigating Childhood Insurance in the US: Insights into Medicaid, CHIP, and Uninsurance Dynamics

By MedXY 09/28/2025

A simulation study reveals that 75% of US children experience publicly subsidized insurance or uninsurance periods by age 18, highlighting the impact of state Medicaid policies on pediatric coverage gaps.